SFDA approves registration of Pemazyre for cholangiocarcinoma

November 10, 2025November 10, 2025

Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has approved the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma.Saudi Gazette reportRIYADH — The Saudi Food and Drug Authority (SFDA) has approved the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma.

Previous PostWhy the BBC Is Facing Its Gravest Crisis in DecadesNext PostSonder Abruptly Goes Out of Business After Marriott Terminates Licensing Deal